Breaking News Instant updates and real-time market news.

BMY

Bristol-Myers

$49.25

-0.76 (-1.52%)

, PFE

Pfizer

$32.64

-0.435 (-1.32%)

10:22
10/13/16
10/13
10:22
10/13/16
10:22

On The Fly: Top five analyst downgrades

Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Bristol-Myers (BMY) downgraded to Buy from Conviction Buy at Goldman with analyst Jami Rubin saying disappointing CM-26 data adds a greater level of uncertainty to future trials. 2. Pfizer (PFE) downgraded to Hold from Buy at Jefferies with analyst Jeffrey Holford citing a lack of positive catalysts. 3. Coach (COH) downgraded to Mixed from Positive at OTR Global citing checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers. 4. E-Trade (ETFC) downgraded to Neutral from Buy at BofA/Merrill. 5. Deckers Brands (DECK) downgraded to Negative from Neutral at Susquehanna with analyst Sam Poser saying he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

BMY

Bristol-Myers

$49.25

-0.76 (-1.52%)

PFE

Pfizer

$32.64

-0.435 (-1.32%)

COH

Coach

$35.67

-0.86 (-2.35%)

ETFC

E-Trade

$28.71

-0.22 (-0.76%)

DECK

Deckers Brands

$56.25

-4.73 (-7.76%)

  • 27

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 07

    Nov

BMY Bristol-Myers
$49.25

-0.76 (-1.52%)

10/10/16
LEER
10/10/16
NO CHANGE
LEER
Outperform
Leerink sees Bristol-Myers sliding after Merck's 'spectacular' Keytruda data
Leerink analyst Seamus Fernandez said Bristol-Myers' (BMY) Checkmate-026 data presented at the European Society of Medical Oncology meeting was disappointing, noting there was no signal of benefit on progression-free survival or overall survival and only "modest differentiation" on response rate in the 88 patients with PDL1 biomarker positivity greater than or equal to 50%. Meanwhile, Merck (MRK) presented "spectacular" data for Keytruda monotherapy at the meeting, said Fernandez, who expects Bristol shares to be down "significantly" today in light of the meeting presentations. The analyst, who still thinks Bristol has a significant opportunity to compete with Merck's Keytruda in the PDL1 high portion of the market, keeps an Outperform rating on Bristol shares, which are down nearly 6% in pre-market trading.
09/27/16
PIPR
09/27/16
NO CHANGE
Target $62
PIPR
Neutral
Bristol-Myers price target lowered to $62 from $65 at Piper Jaffray
Piper Jaffray analyst Richard Purkiss lowered his price target for Bristol-Myers Squibb (BMY) to $62 saying he sees the company ceding Opdivo's early-mover advantage in lung cancer to competitors. The analyst expects to see details from Roche's (RHHBY) positive OAK trial of Tecentriq vs. docetaxel in non-small cell lung cancer at the upcoming ESMO meeting. Purkiss also expects to see details from Merck's (MRK) positive KEYNOTE-024 trial of Keytruda. The analyst lowered his post-2016 Opdivo forecasts and reiterates a Neutral rating on Bristol shares.
10/13/16
GSCO
10/13/16
DOWNGRADE
GSCO
Buy
Bristol-Myers downgraded to Buy from Conviction Buy at Goldman
Goldman analyst Jami Rubin removed Bristol-Myers from the Conviction Buy List and lowered its price target to $67 from $75 saying disappointing CM-26 data adds a greater level of uncertainty to future trials. He continues to believe is well positioned for 2017, and view the shares as very attractive over the long-term.
09/28/16
ROTH
09/28/16
NO CHANGE
Target $23
ROTH
Buy
Nektar price target raised to $23 from $19 at Roth Capital
Roth Capital analyst Michael Higgins raised his price target for Nektar (NKTR) to $23 from $19 after the company and Bristol-Myers (BMY) announced a clinical collaboration to evaluate the combination of the latter's anti-PD-1 antibody, Opdivo, with NKTR-214. The analyst reiterates a Buy rating on Nektar's shares.
PFE Pfizer
$32.64

-0.435 (-1.32%)

08/23/16
RHCO
08/23/16
DOWNGRADE
RHCO
Neutral
Medivation downgraded to Neutral from Buy at SunTrust
Medivation (MDVN) has agreed to be acquired by Pfizer (PFE) for $81.50 per share.
09/14/16
BMOC
09/14/16
NO CHANGE
BMOC
Pfizer should exceed fiscal 2016 guidance, says BMO Capital
BMO Capital analyst Alex Arfaei says that Pfizer should exceed its fiscal 2016 guidance. The analyst says that Medivation, which Pfizer agreed to acquire, gives Pfizer another growth driver. Additionally, Pfizer has a number of other "high margin specialty drugs," according to the analyst. He says that the stock's dividend yield is "attractive," and he keeps a $40 price target and Outperform rating on the shares.
10/07/16
ROTH
10/07/16
NO CHANGE
Target $160
ROTH
Buy
ICU Medical price target raised to $160 from $132 at Roth Capital
Roth Capital analyst Chris Lewis raised his price target for ICU Medical (ICUI) to $160 from $132 after the company announced an agreement to acquire Hospira Infusion Systems from Pfizer (PFE) for $1B. The analyst is overall positive on the deal as it removes the long-standing customer concentration overhang and grows ICU Medical into a legitimate pure-play infusion therapy company with a complete product portfolio. The company also preannounced Q3 preliminary results above expectations, he notes. Lewis reiterates a Buy rating on ICU Medical's shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
COH Coach
$35.67

-0.86 (-2.35%)

09/30/16
09/30/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Amazon.com (AMZN) initiated with a Buy at Guggenheim. 2. Wal-Mart (WMT) initiated with an Overweight at KeyBanc and a Buy at Guggenheim. 3. Harley-Davidson (HOG) initiated with a Hold at Jefferies. 4. Coach (COH) was initiated with a Buy at Guggenheim while the firm initiated Michael Kors (KORS) with a Neutral. 5. First Solar (FSLR) initiated with a Buy at Williams Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/13/16
OTRG
10/13/16
DOWNGRADE
OTRG
Mixed
Coach downgraded to Mixed from Positive at OTR Global
OTR Global downgraded Coach to Mixed following checks that indicate less competitive offerings, reduced promotions, and feedback of some share loss by store managers.
10/05/16
KEYB
10/05/16
DOWNGRADE
KEYB
Sector Weight
Vera Bradley downgraded to Sector Weight at KeyBanc
As previously reported, KeyBanc analyst Edward Yruma downgraded Vera Bradley (VRA) to Sector Weight from Overweight, as he sees risk to its earnings. Yruma thinks the brand's reboot has been successful, as reflected by the 20% year-over-year rise in shares, but with gross margins at their highest since 2010, sales need to increase to drive earnings, he tells investors. In the handbag space, Yruma prefers Coach (COH), on which he keeps an Overweight rating.
10/04/16
WELS
10/04/16
NO CHANGE
WELS
Outperform
Coach still has upside as share retaken from Michael Kors, says Wells Fargo
Wells Fargo analyst Ike Boruchow believes that after Coach (COH) posted its first positive North American comp last quarter in over three years that it appears many investors have recently "moved on," viewing the turnaround story as played out. However, he thinks here is a long way to go should the brand continue to execute and finds it interesting that while investors were keenly aware of how much market share Michael Kors (KORS) was stealing over the past seven years, now it "doesn't seem like anyone is paying attention" as Coach finally takes back share at Kors' expense. Boruchow reiterate an Outperform rating and $46-$48 price target range on Coach share.
ETFC E-Trade
$28.71

-0.22 (-0.76%)

09/30/16
SBSH
09/30/16
NO CHANGE
Target $31.5
SBSH
Neutral
Citi 'inclined to fade' September rally in TD Ameritrade
Citi analyst William Katz attributes the 5% September rally in shares of TD Ameritrade (AMTD) to speculation around a possible acquisition of E-Trade (ETFC). The rally in the shares likely discounts the earnings accretion from such a merger, Katz tells investors in a research note. He believes TD Ameritrade shares at current levels leave "no room for a bad outcome," which he defines as the company deciding not to pursue the deal or E-Trade acquiring Scottrade. As such, Katz says he's "inclined to fade the rally" in TD Ameritrade. The analyst has a Neutral rating on the shares with a $31.50 price target. TD Ameritrade is up 2% in early trading to $35.08.
09/30/16
WELS
09/30/16
NO CHANGE
WELS
Multiple companies could pursue Scottrade, says Wells Fargo
After Bloomberg reported that Scottrade is working with an adviser to explore selling itself, and the article mentioned Ameritrade (AMTD) as a potential suitor, Wells Fargo says that Charles Schwab (SCHW) and E-Trade (ETFC) could "also have interest" in Scottrade. The firm says that the deal could be accretive by double digit percentage levels for all of the potential suitors named. However, ti says that Ameritrade "may be the most logical buyer," since E-Trade just closed on an acquisition and Schwab has sought to place less emphasis trading. The firm keeps an Outperform rating on E-Trade and Market Perform ratings on Schwab and TD Ameritrade.
10/13/16
BOFA
10/13/16
DOWNGRADE
Target $33
BOFA
Neutral
E-Trade downgraded to Neutral from Buy at BofA/Merrill
BofA/Merrill analyst Michael Carrier downgraded E-Trade to Neutral and raised its price target to $33 from $31.
09/26/16
09/26/16
INITIATION

On The Fly: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Apache (APA) initiated with a Neutral at MUFG. 2. Marriott (MAR) was initiated with a Buy at Goldman while the firm initiated La Quinta (LQ) with a Sell. Goldman also initiated Red Rock Resorts (RRR), Hyatt (H), and Wyndham (WYN) with a Neutral. 3. Charles Schwab (SCHW) was initiated with an Overweight at Morgan Stanley while the firm initiated E-Trade (ETFC) and TD Ameritrade (AMTD) with an Equal Weight. 4. Valvoline (VVV) initiated with a Buy at Seaport Global. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
DECK Deckers Brands
$56.25

-4.73 (-7.76%)

10/13/16
SUSQ
10/13/16
DOWNGRADE
Target $49
SUSQ
Negative
Deckers Brands downgraded to Negative at Susquehanna
As reported previously, Susquehanna analyst Sam Poser downgraded Deckers Brands to Negative from Neutral as he believes the health of the UGG brand is clearly at risk as the company has already started promotional activity. The analyst also reduced his estimates and believes gross margin improvement will be below expectations. Poser lowered his price target to $49 from $59 on Deckers Brands shares.
08/15/16
TLSY
08/15/16
UPGRADE
TLSY
Outperform
Deckers Brands upgraded to Outperform from Market Perform at Telsey Advisory
08/15/16
08/15/16
UPGRADE

Outperform
Deckers Brands upgraded to Outperform at Telsey Advisory
As previously reported, Telsey Advisory upgraded Deckers to Outperform from Market Perform and raised its price target to $78 from $68. Analyst Kelly Chen said Deck has become more than just a winter story, although she expects weather will not be as unfavorable as it was last year, as new management is implementing real and meaningful changes that can improve sales and profitability, and drive growth over the long term. Chen highlights new and compelling product innovation, a more advanced and disciplined approach to segmenting the product and the distribution, and taking a hard line on driving efficiencies across the organization by reducing unproductive SKUs, improving lead times and closing stores that are not meeting the company's targets.
09/30/16
GUGG
09/30/16
INITIATION
GUGG
Neutral
Deckers Brands initiated with a Neutral at Guggenheim

TODAY'S FREE FLY STORIES

AJRD

Aerojet Rocketdyne

$32.30

0.55 (1.73%)

07:52
09/22/17
09/22
07:52
09/22/17
07:52
Upgrade
Aerojet Rocketdyne rating change  »

Aerojet Rocketdyne…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMAT

Applied Materials

$47.15

-0.13 (-0.27%)

07:50
09/22/17
09/22
07:50
09/22/17
07:50
Conference/Events
Applied Materials to host analyst meeting »

Analyst meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

07:50
09/22/17
09/22
07:50
09/22/17
07:50
General news
Fedspeak returned from the blackout period »

Fedspeak returned from…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:49
09/22/17
09/22
07:49
09/22/17
07:49
Hot Stocks
Phillips 66 Partners to sell $750M of Series A preferred units »

Phillips 66 Partners LP…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Phillips 66 Partners announces $2.4B acquisition of interests from Phillips 66 »

Phillips 66 Partners…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VSAR

Versartis

$21.60

-0.25 (-1.14%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Recommendations
Versartis analyst commentary  »

Cantor still sees 55%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EXEL

Exelixis

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Downgrade
Exelixis rating change  »

Exelixis downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 25

    Sep

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

07:48
09/22/17
09/22
07:48
09/22/17
07:48
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners »

Phillips 66 Partners to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

X

U.S. Steel

$24.66

-1.13 (-4.38%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Technical Analysis
Technical View: U.S. Steel falls in early trading, analyst action »

Shares were last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

, PSX

Phillips 66

$89.14

0.07 (0.08%)

07:47
09/22/17
09/22
07:47
09/22/17
07:47
Hot Stocks
Breaking Hot Stocks news story on Phillips 66 Partners, Phillips 66 »

Phillips 66 Partners to…

PSXP

Phillips 66 Partners

$48.52

0.37 (0.77%)

PSX

Phillips 66

$89.14

0.07 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:45
09/22/17
09/22
07:45
09/22/17
07:45
Recommendations
Zimmer Biomet analyst commentary  »

Value investors should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:45
09/22/17
09/22
07:45
09/22/17
07:45
General news
N.Y. FX Outlook »

N.Y. FX Outlook: The…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

, TCEHY

Tencent

$44.15

-0.15 (-0.34%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Periodicals
Alibaba, Tencent look towards emerging markets in mobile-payments race, WSJ says »

Chinese companies Alibaba…

BABA

Alibaba

$177.39

-0.56 (-0.31%)

TCEHY

Tencent

$44.15

-0.15 (-0.34%)

AAPL

Apple

$153.39

-2.68 (-1.72%)

GOOG

Alphabet

$932.45

0.87 (0.09%)

GOOGL

Alphabet Class A

$947.55

0.01 (0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

  • 22

    Oct

  • 29

    Nov

SPR

Spirit AeroSystems

$78.90

0.76 (0.97%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Spirit AeroSystems to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

AERI

Aerie Pharmaceuticals

$51.45

-1.95 (-3.65%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Recommendations
Aerie Pharmaceuticals analyst commentary  »

Aerie pullback on AdComm…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 28

    Feb

CSCO

Cisco

$32.70

0.1 (0.31%)

07:44
09/22/17
09/22
07:44
09/22/17
07:44
Conference/Events
Cisco management to meet with Deutsche Bank »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

  • 25

    Sep

  • 26

    Sep

  • 28

    Sep

  • 29

    Sep

  • 05

    Oct

  • 06

    Oct

  • 18

    Oct

  • 19

    Oct

  • 22

    Oct

  • 15

    Nov

  • 07

    Dec

  • 11

    Dec

EFX

Equifax

$98.25

2.25 (2.34%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Technical Analysis
Technical View: Equifax trades higher, analyst action »

Shares are back well…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

AA

Alcoa

$46.25

-1.25 (-2.63%)

07:41
09/22/17
09/22
07:41
09/22/17
07:41
Downgrade
Alcoa rating change  »

Alcoa downgraded to Hold,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KMX

CarMax

$68.84

0.17 (0.25%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Earnings
CarMax reports Q2 EPS 98c, consensus 95c »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

SYK

Stryker

$140.67

-2.04 (-1.43%)

, ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

07:40
09/22/17
09/22
07:40
09/22/17
07:40
Recommendations
Stryker, Zimmer Biomet analyst commentary  »

Growth investors should…

SYK

Stryker

$140.67

-2.04 (-1.43%)

ZBH

Zimmer Biomet

$113.06

-2.92 (-2.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Oct

SAVE

Spirit Airlines

$34.01

1.31 (4.01%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Conference/Events
Spirit Airlines to host investor meeting »

Investor meeting to be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

IBM

IBM

$145.26

-0.62 (-0.43%)

, WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

07:39
09/22/17
09/22
07:39
09/22/17
07:39
Hot Stocks
IBM announces new agreement with Walgreens to deploy IBM retail analytics »

IBM (IBM) announced a new…

IBM

IBM

$145.26

-0.62 (-0.43%)

WBA

Walgreens Boots Alliance

$78.20

-0.64 (-0.81%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 23

    Sep

  • 22

    Oct

  • 25

    Oct

  • 15

    Nov

07:38
09/22/17
09/22
07:38
09/22/17
07:38
Conference/Events
Federal Reserve Bank of Dallas President participates in a conference »

Dallas Federal Reserve…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.